NantKwest Employee Directory
Biotechnology ResearchCalifornia, United States11-50 Employees
NantKwest is a biotechnology research company headquartered at 9920 Jefferson Boulevard, Culver City, California 90232, United States, focusing on immunotherapy using natural killer (NK) cells. It develops an off-the-shelf activated NK cell platform intended to treat cancer, infectious diseases, and inflammatory diseases, with the potential for outpatient administration and no need for individualized patient matching, and it can be engineered to include chimeric antigen receptors (CARs) or antibody receptors to enhance targeting. As a clinical-stage organization, NantKwest conducts Phase 1 trials in the United States, Canada, and Europe to evaluate NK cell–based therapies across oncology, infectious diseases, and inflammatory conditions. The company has pursued Phase 2 studies through its QUILT program, including QUILT-3.063 examining a combination of an IL-15 superagonist (N-803), off-the-shelf CD16-targeted NK cells (haNK), and Avelumab for Merkel cell carcinoma, and QUILT-88 in pancreatic cancer involving aldoxorubicin. NantKwest trades on the NASDAQ exchange under the ticker NK and has a workforce of 11-50 employees.